AUR-AFE4-TTM1-A-1-1-R-A742-41
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.230
- TGF_BETA_SIGNALING+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- IL6_JAK_STAT3_SIGNALING+0.200
- HEME_METABOLISM+0.140
- ESTROGEN_RESPONSE_LATE+0.130
- INFLAMMATORY_RESPONSE+0.090
- TNFA_SIGNALING_VIA_NFKB+0.090
- COAGULATION+0.060
- COMPLEMENT+0.060
Top 10 suppressed
- E2F_TARGETS-0.490
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V1-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- MYC_TARGETS_V2-0.390
- HEDGEHOG_SIGNALING-0.330
- GLYCOLYSIS-0.320
- DNA_REPAIR-0.240
- HYPOXIA-0.220
- OXIDATIVE_PHOSPHORYLATION-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1008 | — | — | 0.763 |
| 2 | TCGA-05-4384-01A-01R-1755-07 | — | cohortA2 | 0.745 |
| 3 | s_150203_5a | EPN | Posterior Fossa EPN | 0.740 |
| 4 | SRR6079994 | — | — | 0.739 |
| 5 | TCGA-CF-A9FM-01A-11R-A38B-07 | — | — | 0.712 |
| 6 | MNG795 | — | — | 0.705 |
| 7 | TCGA-86-8056-01A-11R-2241-07 | — | cohortA1 | 0.701 |
| 8 | TCGA-55-8206-01A-11R-2241-07 | — | cohortA1 | 0.699 |
| 9 | TCGA-CV-A45X-01A-21R-A24Z-07 | — | — | 0.696 |
| 10 | C3N-02828 | — | cohortA1 | 0.695 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |